Walder Wyss with Pharmakon Advisors on CHF 250 m financing for Idorsia
Walder Wyss advised funds managed by Pharmakon Advisors — an investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds — in connection with their role as investors in a CHF 250 million senior secured financing for Idorsia (SIX: IDIA), a Swiss biopharmaceutical company specialised in the discovery, development, and commercialisation of innovative molecules.
The Walder Wyss team
The Walder Wyss team was led by counsel Tervel Stoyanov (banking & finance) and included managing associate Valentin Wiesner (banking & finance), partner Maurus Winzap (tax) and managing associate Ursina Gremminger (tax).
